Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Raw Materials (2016 - 2026)

Orthofix Medical has reported Raw Materials over the past 16 years, most recently at $24.9 million for Q1 2026.

  • For the quarter ending Q1 2026, Raw Materials fell 4.71% year-over-year to $24.9 million, compared with a TTM value of $24.9 million through Mar 2026, down 4.71%, and an annual FY2025 reading of $22.9 million, down 15.88% over the prior year.
  • Raw Materials came in at $24.9 million for Q1 2026, up from $22.9 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $30.9 million in Q1 2024 to a low of $11.3 million in Q1 2022.
  • Median Raw Materials over the past 5 years was $26.1 million (2025), compared with a mean of $24.0 million.
  • The sharpest move saw Raw Materials surged 119.11% in 2022, then dropped 15.88% in 2025.
  • Over 5 years, Raw Materials stood at $17.0 million in 2022, then soared by 66.66% to $28.4 million in 2023, then fell by 4.26% to $27.2 million in 2024, then dropped by 15.88% to $22.9 million in 2025, then rose by 8.82% to $24.9 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Raw Materials are $24.9 million (Q1 2026), $22.9 million (Q4 2025), and $24.8 million (Q3 2025).